HLA Class II Genotyping in Chronic HCV Patients

Raouf, May; Ghoneim, Faika Mahmoud; Aly, H.A.; Alkafash, Dalal M. Nasr Eldin; Hanafi, Nesrine Fathi; Zid, Ahmed Elsayed

doi:10.12816/0046275

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of oral Direct-Acting Antivirals (DAAs), which directly block the HCV replication cycle and target three key HCV genome regions (NS3/4A protease, NS5A, and NS5B RNA-dependent polymerase) led to a significant advancement in HCV therapy [3] . Raouf et al [4] have documented the impact of numerous variables on the onset and course of disease, including genetic variants, host factors (age, sex, environment, and related medical conditions) and viral factors like viral genotype and viral load.…”

Section: Introductionmentioning

confidence: 99%

Clinical Significance of HLA DPB1 (SNPrs3116996 & SNPRs2071025) Gene Polymorphism in Liver Cirrhosis Development among Egyptian Patients with Chronic HCV Infection

2024

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Chronic liver disease, which can lead to cirrhosis and hepatocellular carcinoma (HCC), is mostly caused by hepatitis C. Objective: We aimed to clarify the association between HLADPB1 expression and chronic HCV infection in Egyptian patients. Patients and methods: 85 adult participants were enrolled in this study. They were divided into three groups: Group 1 included 20 cirrhotic patients with HCV, group 2 included 20 chronic HCV patients and group 3 included 45 healthy controls. HLADPB1SNPrs3116996 and HLADPB1 SNPRs2071025 polymorphism were assessed. Results: There was significant higher frequency of HLADPB1SNPrs3116996 genotype TA in cirrhotic HCV patients in comparison with chronic HCV patients and healthy controls (40%, 15% and 4.4 % respectively; p=0.002). Also, cirrhotic HCV group had significantly higher frequency of A allele when compared to chronic HCV group and healthy controls (20.0%, 7.5% and 2.2% respectively; p0.001). HLADPB1 (SNPRs2071025) genotypes AG in patients with cirrhotic HCV, chronic HCV patients and healthy control were 45%, 25% and 8.9% respectively with significant Pvalue (0.001). In addition, there was significantly higher allele G frequency among the cirrhotic HCV patients (22.5%) followed by chronic HCV patients (17.5%) compared to controls (4.4%) with significant p-value (0.002). Conclusion: HLADPB1SNPrs3116996 genotype TA and HLADPB1 SNPRs2071025 genotype AG carry risk of liver cirrhosis development in patients with chronic HCV infection and deterioration of clinical and biochemical parameters.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Significance of HLA DPB1 (SNPrs3116996 & SNPRs2071025) Gene Polymorphism in Liver Cirrhosis Development among Egyptian Patients with Chronic HCV Infection

2024

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

HLA Class II Genotyping in Chronic HCV Patients

Cited by 1 publication

References 0 publications

Clinical Significance of HLA DPB1 (SNPrs3116996 & SNPRs2071025) Gene Polymorphism in Liver Cirrhosis Development among Egyptian Patients with Chronic HCV Infection

Clinical Significance of HLA DPB1 (SNPrs3116996 & SNPRs2071025) Gene Polymorphism in Liver Cirrhosis Development among Egyptian Patients with Chronic HCV Infection

Contact Info

Product

Resources

About